This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy‐induced amenorrhea. (20th November 2017)
Record Type:
Journal Article
Title:
Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy‐induced amenorrhea. (20th November 2017)
Main Title:
Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy‐induced amenorrhea
Key Points: In this study, the risk of a return to menses and/or premenopausal estradiol/follicle‐stimulating hormone levels by 30 months after a switch from adjuvant tamoxifen to aromatase inhibitor therapy in women with postmenopausal estradiol levels at the time of the switch was 15.2% (38 of 250 patients) for women who had chemotherapy‐induced amenorrhea and were aged younger than 50 years at the time of breast cancer diagnosis. The risk was 1.2% (1 in 79 women) for women who were aged 50 to 54 years but still were premenopausal at the time of breast cancer diagnosis.